Dimethyl lithospermate BCAS# 875313-64-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 875313-64-7 | SDF | Download SDF |
| PubChem ID | 73349618 | Appearance | Powder |
| Formula | C38H34O16 | M.Wt | 746.67 |
| Type of Compound | Phenylpropanoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | [(2R)-3-(3,4-dihydroxyphenyl)-1-methoxy-1-oxopropan-2-yl] (2R,3R)-2-(3,4-dihydroxyphenyl)-4-[(E)-3-[(2R)-3-(3,4-dihydroxyphenyl)-1-methoxy-1-oxopropan-2-yl]oxy-3-oxoprop-1-enyl]-7-hydroxy-2,3-dihydro-1-benzofuran-3-carboxylate | ||
| SMILES | COC(=O)C(CC1=CC(=C(C=C1)O)O)OC(=O)C=CC2=C3C(C(OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)OC(CC5=CC(=C(C=C5)O)O)C(=O)OC | ||
| Standard InChIKey | DHYLGBJCEGEBGQ-QIBPRZLVSA-N | ||
| Standard InChI | InChI=1S/C38H34O16/c1-50-36(47)29(15-18-3-8-22(39)26(43)13-18)52-31(46)12-7-20-5-11-25(42)35-32(20)33(34(54-35)21-6-10-24(41)28(45)17-21)38(49)53-30(37(48)51-2)16-19-4-9-23(40)27(44)14-19/h3-14,17,29-30,33-34,39-45H,15-16H2,1-2H3/b12-7+/t29-,30-,33-,34+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Dimethyl lithospermate B is a highly potent natural antioxidant and antidiabetic polyphenol with unknown mode of action.Dimethyl lithospermate B slows inactivation of INa, leading to increased inward current during the early phases of the action potential (AP), might be an excellent candidate for a Na(+) channel agonist; it is effective in eliminating the arrhythmogenic substrate responsible for the Brugada syndrome and that it deserves further study as a pharmacological adjunct to implanted cardioverter/defibrillator usage. |
| Targets | Calcium Channel | Sodium Channel | Potassium Channel |
| In vivo | Dimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome.[Pubmed: 16534004]Circulation. 2006 Mar 21;113(11):1393-400.Dimethyl lithospermate B (dmLSB) is an extract of Danshen, a traditional Chinese herbal remedy, which slows inactivation of INa, leading to increased inward current during the early phases of the action potential (AP). We hypothesized that this action would be antiarrhythmic in the setting of Brugada syndrome.
|
| Kinase Assay | A novel Na+ channel agonist, dimethyl lithospermate B, slows Na+ current inactivation and increases action potential duration in isolated rat ventricular myocytes.[Pubmed: 15504759]Br J Pharmacol. 2004 Nov;143(6):765-73.Voltage-gated Na(+) channel blockers have been widely used as local anaesthetics and antiarrhythmic agents. It has recently been proposed that Na(+) channel agonists can be used as inotropic agents. |
Dimethyl lithospermate B Dilution Calculator
Dimethyl lithospermate B Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.3393 mL | 6.6964 mL | 13.3928 mL | 26.7856 mL | 33.482 mL |
| 5 mM | 0.2679 mL | 1.3393 mL | 2.6786 mL | 5.3571 mL | 6.6964 mL |
| 10 mM | 0.1339 mL | 0.6696 mL | 1.3393 mL | 2.6786 mL | 3.3482 mL |
| 50 mM | 0.0268 mL | 0.1339 mL | 0.2679 mL | 0.5357 mL | 0.6696 mL |
| 100 mM | 0.0134 mL | 0.067 mL | 0.1339 mL | 0.2679 mL | 0.3348 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Lusianthridin
Catalog No.:BCN3689
CAS No.:87530-30-1
- YIL 781
Catalog No.:BCC7826
CAS No.:875258-85-8
- Tenacissoside X
Catalog No.:BCN8354
CAS No.:875057-87-7
- H-D-Phg-OH
Catalog No.:BCC3313
CAS No.:875-74-1
- Boc-D-Cys(Trt)-OH
Catalog No.:BCC3381
CAS No.:87494-13-1
- ZK 756326
Catalog No.:BCC7413
CAS No.:874911-96-3
- LY2183240
Catalog No.:BCC1718
CAS No.:874902-19-9
- L-741,742 hydrochloride
Catalog No.:BCC5696
CAS No.:874882-93-6
- Isamoltane hemifumarate
Catalog No.:BCC6879
CAS No.:874882-92-5
- Toceranib phosphate
Catalog No.:BCC2006
CAS No.:874819-74-6
- Dihydroajugapitin
Catalog No.:BCN4421
CAS No.:87480-84-0
- Liriope muscari baily saponins C
Catalog No.:BCN2340
CAS No.:87480-46-4
- JNJ-26481585
Catalog No.:BCC2147
CAS No.:875320-29-9
- MGCD-265
Catalog No.:BCC2479
CAS No.:875337-44-3
- Anacetrapib (MK-0859)
Catalog No.:BCC2327
CAS No.:875446-37-0
- H-D-Tyr-OtBu
Catalog No.:BCC3136
CAS No.:87553-74-0
- ent-14,15-Dinor-13-oxolabda-8(17),11-dien-18-oic acid
Catalog No.:BCN1319
CAS No.:875585-30-1
- Randaiol
Catalog No.:BCN4002
CAS No.:87562-14-9
- Kelampayoside A
Catalog No.:BCN4422
CAS No.:87562-76-3
- PPY A
Catalog No.:BCC3895
CAS No.:875634-01-8
- cis-3,4-Dihydroxy-beta-ionone
Catalog No.:BCN6694
CAS No.:875666-39-0
- LXR-623
Catalog No.:BCC4273
CAS No.:875787-07-8
- (+)-Lyoniresinol 9'-O-glucoside
Catalog No.:BCN4832
CAS No.:87585-32-8
- Smyrindioloside
Catalog No.:BCN4423
CAS No.:87592-77-6
Dimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome.[Pubmed:16534004]
Circulation. 2006 Mar 21;113(11):1393-400.
BACKGROUND: Dimethyl lithospermate B (dmLSB) is an extract of Danshen, a traditional Chinese herbal remedy, which slows inactivation of INa, leading to increased inward current during the early phases of the action potential (AP). We hypothesized that this action would be antiarrhythmic in the setting of Brugada syndrome. METHODS AND RESULTS: The Brugada syndrome phenotype was created in canine arterially perfused right ventricular wedge preparations with the use of either terfenadine or verapamil to inhibit INa and ICa or pinacidil to activate IK-ATP. AP recordings were simultaneously recorded from epicardial and endocardial sites together with an ECG. Terfenadine, verapamil, and pinacidil each induced all-or-none repolarization at some epicardial sites but not others, leading to ST-segment elevation as well as an increase in both epicardial and transmural dispersions of repolarization (EDR and TDR, respectively) from 12.9+/-9.6 to 107.0+/-54.8 ms and from 22.4+/-8.1 to 82.2+/-37.4 ms, respectively (P<0.05; n=9). Under these conditions, phase 2 reentry developed as the epicardial AP dome propagated from sites where it was maintained to sites at which it was lost, generating closely coupled extrasystoles and ventricular tachycardia and fibrillation. Addition of dmLSB (10 micromol/L) to the coronary perfusate restored the epicardial AP dome, reduced EDR and TDR to 12.4+/-18.1 and 24.4+/-26.7 ms, respectively (P<0.05; n=9), and abolished phase 2 reentry-induced extrasystoles and ventricular tachycardia and fibrillation in 9 of 9 preparations. CONCLUSIONS: Our data suggest that dmLSB is effective in eliminating the arrhythmogenic substrate responsible for the Brugada syndrome and that it deserves further study as a pharmacological adjunct to implanted cardioverter/defibrillator usage.
Synthesis of a dual-labeled probe of dimethyl lithospermate B with photochemical and fluorescent properties.[Pubmed:22124203]
Molecules. 2011 Nov 28;16(12):9886-99.
Dimethyl lithosermate B (DLB) is a highly potent natural antioxidant and antidiabetic polyphenol with unknown mode of action. To determine its cellular targets, a photochemical and fluorescent dimethyl lithopermate B probe was designed and efficiently synthesized. The dual-labeled chemical probe for biological application was evaluated by UV and fluorescence to determine its electrochemical absorption and emission properties. This probe could be valuable for investigating ligand-protein interactions and subcellular localization.
A novel Na+ channel agonist, dimethyl lithospermate B, slows Na+ current inactivation and increases action potential duration in isolated rat ventricular myocytes.[Pubmed:15504759]
Br J Pharmacol. 2004 Nov;143(6):765-73.
Voltage-gated Na(+) channel blockers have been widely used as local anaesthetics and antiarrhythmic agents. It has recently been proposed that Na(+) channel agonists can be used as inotropic agents. Here, we report the identification of a natural substance that acts as a Na(+) channel agonist. Using the patch-clamp technique in isolated rat ventricular myocytes, we investigated the electrophysiological effects of the substances isolated from the root extract of Salvia miltiorrhiza, which is known as 'Danshen' in Asian traditional medicine. By the intensive activity-guided fractionation, we identified Dimethyl lithospermate B (dmLSB) as the most active component, while LSB, which is the major component of the extract, showed negligible electrophysiological effect. Action potential duration (APD(90)) was increased by 20 microM dmLSB from 58.8 +/- 12.1 to 202.3 +/- 9.5 ms. In spite of the prolonged APD, no early after-depolarization (EAD) was observed. dmLSB had no noticeable effect on K(+) or Ca(2+) currents, but selectively affected Na(+) currents (I(Na)). dmLSB slowed the inactivation kinetics of I(Na) by increasing the proportion of slowly inactivating component without inducing any persistent I(Na). The relative amplitude of slow component compared to the peak fast I(Na) was increased dose dependently by dmLSB (EC(50) = 20 microM). Voltage dependence of inactivation was not affected by dmLSB, while voltage dependence of activation shifted by 5 mV to the depolarised direction. Since the APD prolongation by dmLSB did not provoke EAD, which is thought as a possible mechanism for the proarrhythmia seen in other Na(+) channel agonists, dmLSB might be an excellent candidate for a Na(+) channel agonist.
